Home » Stocks » Celsion

Celsion Corporation (CLSN)

Stock Price: $1.15 USD -0.03 (-2.54%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 32.00M
Revenue (ttm) 500,000
Net Income (ttm) -19.54M
Shares Out 33.22M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.15
Previous Close $1.18
Change ($) -0.03
Change (%) -2.54%
Day's Open 1.18
Day's Range 1.12 - 1.19
Day's Volume 1,199,292
52-Week Range 0.69 - 6.50

More Stats

Market Cap 32.00M
Enterprise Value 37.59M
Earnings Date (est) Aug 14, 2020
Ex-Dividend Date n/a
Shares Outstanding 33.22M
Float 28.83M
EPS (basic) -0.84
EPS (diluted) -0.83
FCF / Share -0.77
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.62M
Short Ratio 0.30
Short % of Float 5.85%
Beta 2.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 64.00
PB Ratio 2.42
Revenue 500,000
Operating Income -20.47M
Net Income -19.54M
Free Cash Flow -19.91M
Net Cash -5.59M
Net Cash / Share -0.20
Gross Margin -2,513.06%
Operating Margin -4,094.18%
Profit Margin -3,908.20%
FCF Margin -3,982.08%
ROA -30.34%
ROE -103.93%
ROIC -56.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.20*
(265.22% upside)
Low
4.00
Current: $1.15
High
4.41
Target: 4.20
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.500.500.500.500.500.500.50-2.00-
Revenue Growth0%0%0%0%0%0%----
Gross Profit0.500.500.500.500.500.500.50-2.00-
Operating Income-20.57-21.07-18.47-20.65-20.85-24.72-15.41-22.14-23.02-19.64
Net Income-16.85-11.88-20.40-22.05-22.46-25.49-8.25-26.57-23.22-18.82
Shares Outstanding21.8317.587.631.851.561.320.970.550.330.20
Earnings Per Share-0.77-0.68-2.72-11.89-14.42-19.32-13.30-48.16-70.00-95.76
Operating Cash Flow-20.26-7.04-16.64-18.38-20.83-21.35-9.53-22.14-22.74-13.37
Capital Expenditures-0.35-0.14-0.04-0.06-0.11-0.67-0.06-0.61-0.57-0.01
Free Cash Flow-20.61-7.18-16.68-18.44-20.94-22.03-9.58-22.76-23.32-13.37
Cash & Equivalents6.8813.3524.174.3020.0736.8642.8723.0330.301.53
Total Debt11.349.42-2.566.429.715.015.070.180.18
Net Cash / Debt-4.463.9424.171.7413.6427.1537.8617.9630.121.35
Assets38.2846.8647.5130.8549.0366.6945.6725.3632.652.53
Liabilities23.7225.9920.8124.1228.6433.8714.1513.406.467.10
Book Value14.5620.8626.706.7320.3932.8331.5211.9626.19-4.58
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Celsion Corporation
Country United States
Employees 29
CEO Michael H. Tardugno

Stock Information

Ticker Symbol CLSN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLSN
IPO Date March 5, 1985

Description

Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.